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the economic impact of rheumatoid arthritis alone is substantial
with the indirect productivity or income loss as large as the
health care costs.
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OBJECTIVE: To assess the relationship between economic
burden and physical functioning or disease severity in rheu-
matoid arthritis (RA). METHODS: Medline, Embase, BIOSIS,
Derwent Drug File, the Cochrane library and NHS-EED were
searched on 12th March 2007 for cost-of-illness (COI) and cost-
effectiveness studies in RA. RESULTS: A total of 909 unique
citations were retrieved. Nine studies presented COI results; with
seven studies presenting data on the relationship between direct
and indirect costs and physical functioning or disease severity.
The Health Assessment Questionnaire (HAQ) was used in three
studies to assess functional ability. Higher HAQ scores at base-
line were found to be signiﬁcant predictors of higher future direct
costs in two studies. A third study used both HAQ and the
Hannover Functional Status Questionnaire (FFbH) to assess
functional ability. For patients with an HAQ score <1.2 (or
>70% of full FFbH function) the mean annual direct costs were
€3225 and indirect costs were €8,811; for patients with an HAQ
score between 1.2 and 1.7 (FFbH function of 50 to 70%) mean
annual direct costs were €5,661 and indirect costs were €21,580;
whilst for patients with an HAQ score higher than 1.7 (FFbH
functional status of <50% of normal) mean annual direct costs
were €8,403 and indirect costs were €34,915. A further two
studies using the FFbH conﬁrmed these ﬁndings of increased
costs with decreasing functional ability. Finally, in two studies
assessing the relationship between disease severity and costs,
there was a statistically signiﬁcant difference (p < 0.001) in both
direct and indirect costs for each level increase in disease severity
(based on ACR functional classes I, II, III and IV) and increases
in costs with increasing disease severity categorised as no disabil-
ity, mild, moderate and severe. CONCLUSION: The economic
burden of RA appears highly dependent on both the level of
functional disability and disease severity.
PMS22
ECONOMIC IMPACT OF ALLOPURINOL HYPERSENSITIVITY
SYNDROME
D’Souza AO1, Fuldeore MJ2, Khanna D3, Meissner BL1,
Dabbous OH2
1Xcenda, Palm Harbor, FL, USA, 2TAP Pharmaceutical Products Inc,
Lakeforest, IL, USA, 3UCLA, Los Angeles, CA, USA
OBJECTIVE: The study is an assessment of the economic impact
of allopurinol hypersensitivity syndrome (AHS) in a managed
care population. METHODS: Due to absence of a speciﬁc ICD-9
CM code for AHS, an algorithm was developed using results of
a modiﬁed Delphi process to identify an AHS episode, and assess
its economic impact from claims data. Allopurinol users were
identiﬁed as those who had a prescription during January 1,
2000 to June 30, 2006. Presence of an AHS episode was assessed
during the continuous eligibility period after the ﬁrst allopurinol
prescription. The start date of an AHS episode was termed as the
index AHS date, and overall health care costs were computed
during a six month period before and after the index AHS date.
Statistical differences in costs per patient per six month period
pre- and post- AHS were assessed using paired t-tests; differences
in proportion with non-zero costs were assessed using McNe-
mar’s test. All costs are expressed in 2007 US Dollars.
RESULTS: A total of 417 allopurinol users experienced at least
one AHS episode during the period following their index allopu-
rinol prescription compared to 124,546 users who did not. The
average cost per patient in the six month period following the
index AHS date was $8598 higher than the prior 6-month period
($14,338 vs. $5,740, P < 0.001). The cost increase was evident
for both medical ($12,032 vs. $4,242, P < 0.001) and pharmacy
components ($2,306 vs. $1,498, P < 0.001). The large difference
in medical costs was primarily due to large differences in inpa-
tient costs ($7497 vs. $2335, P < 0.001), as a signiﬁcantly higher
proportion had a hospitalization following the AHS episode
compared to the pre-index AHS period (40.3% vs. 16.8%,
P < 0.001). CONCLUSION: This study found AHS to have a
signiﬁcant economic impact contributing to an almost three fold
increase in overall health care costs.
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OBJECTIVE: The purpose of this study was to calculate the
treatment cost of femoral neck fracture and ﬁnancial burden of
the annual fracture cases at 2007 ﬁnancial level from health
insurance point of view. METHODS: The costs of the treatment
of femoral neck fractures are modeled according to the actually
NHIFA (National Health Insurance Fund Administration) reim-
bursed types of care including acute inpatient care, chronic inpa-
tient care, outpatient care, pharmaceuticals and medical devices,
home care (nursing), cost of traveling or transport, and sick pay.
Cases in which patients were healing following primary treat-
ment (without complications) and cases with complications were
examined separately. The ﬁnancial burden was estimated by
using data from international literature and Hungarian studies
(number of fractures, mortality, ratio of further treatment, etc.)
which were extrapolated for the average health insurance
treatment cost of one patient. Yearly average in 2007:
USD$1 = 183,83 HUF. RESULTS: The cost of patients in active
age-groups cured by primary treatment can vary in a range of
USD$5093–USD$7549 depending on cost level of individual
care and utilization. The cost of patients with complication
(primary treatment and complication) in active age-groups can
reach USD$9317–USD$16049, depending on cost level of indi-
vidual care and utilization. According to our model calculations,
the cost of primary treatment of femoral neck fractures
and essential further treatment represents an annual burden
of USD$22,676,518–USD$32,194,335 for the health insurance
system. CONCLUSION: In order to reduce the incidence of neck
fractures, one should emphasize the importance of current and
future interventions, which projects the possibility of reducing
the ﬁnancial burden at societal level. The real decrease of ﬁnan-
cial burden can be realized by reducing the risk increasing effect
of risk factors of the whole primary treatment on further treat-
ments, following the implementation of well-established and
uniform professional decisions.
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